Who we are

Company timeline

2025

UCLB News

Biopharm advancements

Collaborations

MeiraGTx enters strategic collaboration with Hologen

Read article

2024

Biopharm advancements

Autolus logo

Autolus Therapeutics announces FDA Approval of AUCATZYL®

Read here
Logo

UK Regulator MHRA grants Nanomerics Clinical Trials Authorisation Notice for upcoming OC134 Clinical Trial

Read article
Young girl sitting on a hospital bed holding a teddy.

MeiraGTx’s revolutionary eye gene therapy used at Evelina London

Read article

Spinouts

Conceptual Illustration of neuron cells.

Series A $101m

Trace Neuroscience launches with exclusive license from UCL and $101 million Series A funding

UCLB News

USIT Guide front cover

UCLB and UCL join leading university technology transfer offices to welcome new guidelines on forming software spinout businesses

Read article

Investments

$12m

Gaussion secures $12m to revolutionise battery charging

Read article
Stanhope AI team

Stanhope AI's 'humanlike' machines gain £2.3m boost

Read article

$10m

EpilepsyGTx announces a $10m fundraise

Read more

Social ventures

Man speaking on stage in front of an audience.

UCLB celebrates the Launch of London Social Ventures

Read article

Announcements

2023

Awards

Autolus logo

Autolus named as one of The Guardian's six firms to watch in 2023.

View article

Investments

Orchard Therapeutics announces strategic financing totalling up to $188m.

View article

$30m

MeiraGTx gains $30m strategic investment from Sanofi

Read article
Microscope in lab

$226.5m

UCL partner Apollo Therapeutics receives $226.5m

Read article

Spinouts

Anniversary

UCLB News

Jeremy Hunt, the Chancellor of the Exchequer, and Michelle Donelan, Secretary of State for Science, Innovation and Technology & Anne Lane, CEO, UCLB.

Chancellor visits UCL East as the government announces a boost for university spinouts

View article

Biopharm advancements

Bloomsbury Genetic Therapies logo

Bloomsbury Genetic Therapies receives Orphan Drug Designations from the European Commission and US FDA.

Read more
Blood samples

First European commercial ROCTAVIAN treatment takes place in Germany

Read article

2022

Biopharm advancements

Blood in test tubes

BioMarin announces stable and durable annualised bleed control in the largest Phase 3 gene therapy study in adults with severe Haemophilia A.

View article
Gene therapy

Orchard Therapeutics announces historic agreement making Libmeldy available by NHS England for MLD patients.

View article
Blood samples

First gene therapy for adults with severe Haemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), approved by European Commission (EC)

View article
Freeline logo

Freeline initiates dosing of second cohort in MARVEL-1 trial of FLT190 gene therapy candidate for people with Fabry disease

View article

Investments

Bramble Energy secures £35m

Series B investment round to continue its development of hydrogen fuel cells.

View article

Collaborations

IBS

Engitix announces expanded collaboration and licensing agreement with Takeda to develop new anti-fibrotic therapies in Inflammatory Bowel Disease.

View article

Spinouts

Bloomsbury Genetic Therapies logo

Bloomsbury Genetic Therapies launches with Seed financing of £5m to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases.

View article

2021

Spinouts

Tunnel

UCLB spinout, Senceive, is acquired by Eddyfi/NDT.

View article
Achilles Therapeutics logo

Achilles Therapeutics announces its IPO on NASDAQ.

View article
Satalia

UCL spinout, Satalia is acquired by WPP, the world's largest advertising firm.

View article

Investments

Apollo Therapeutics Logo

Apollo Therapeutics raises £100m

Series A funding to rapidly advance cutting-edge science.

View article

Bramble Energy secures £5m

Series A investment to support the launch of its zero-emissions portable power product range.

View article

Carbon Re secures £1m

seed funding to help energy-intensive industries achieve Net Zero.

View article

Launches

Axovia Therapeutics, backed by Deerfield Management Co., launched to develop transformative medicines for ciliopathies.

View article

Awards

Anne Lane

UCLB's CEO, Anne Lane, receives a Lifetime Achievement Award in recognition of her commitment to commercialisation throughout her career.

View article
Apollo Therapeutics Logo

Apollo Therapeutics wins Praxis Auril KE Deal of the Year, for attracting major investment to empower a unique, multi-university portfolio-based biopharmaceuticals venture.

View article

Biopharm advancements

NovalGen logo

NovalGen doses its first patient in Phase I study in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma.

View article

2020

Investments

Freeline

Freeline receives further $80m

from Syncona in its Series C funding round, to develop curative gene therapies for chronic systemic diseases.

View article

UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm.

View article

Humanloop raises funding to teach AI to learn from humans faster.

View article
UCLTF logo

UCL Technology Fund announces first close of £100m

Advancements

UCL-Ventura CPAP device.

UCL-Ventura CPAP device

UCL supports worldwide dissemination of free-to-access manufacturing instructions for COVID-19 breathing aids.

View article
Award

UCLB wins Knowledge Exchange External Initiative of the Year, for its global dissemination of the UCL-Ventura breathing aid.

View article

Social venture

Paint tube

UCL artist, Onya McCausland launches paint made from coal mine waste.

View article

Biopharm advancements

Orchard Therapeutics makes progress in its mission to help people with rare diseases.

Orchard Therapeutics logo

Orchard announces FDA-granted orphan drug designation for OTL-102 for the treatment of X-linked Chronic Granulomatous Disease.

View article

Orchard announces first patient dosed with OTL-201 gene therapy in Proof of Concept clinical trial.

View article

Spinouts

Freeline

Freeline Therapeutics makes its NASDAQ debut, raising $158.8m

Awards

Odin Vision logoechopoint-logo

Two UCLB spinout companies announced winners at the SEHTA MedTech Business Awards.

View article

2019

Social venture

UCLB social ventures video.

UCLB launches funding for early-stage social ventures.

Watch video
Help Diabetes

NHS England provides online support, developed at UCL, for type 2 diabetes.

View article

Investments

Quell Therapeutics logo

QuellTx raises £35m

Series A financing, backed by Syncona.

View article
echopoint-logo

Echopoint raises £2.8m

to address the 'grey zone' of heart disease treatment.

View article
Achilles Therapeutics logo

Achilles Therapeutics raises £100m

in oversubscribed Series B financing round.

View article

£6.5m

of funding for spinout, AstronauTx for dementia research.

View article

Announcements

Anne Lane

Dr Anne Lane appointed as new Managing Director for UCLB.

View article

Awards

Four UCLB spinout companies are named finalists in the European Lifestars Awards: Ixico, Orchard Therapeutics, Quell Therapeutics, Autolus Therapeutics.

View article

Biopharm advancements

Development of a new gene therapy for the treatment of haemophilia A, licensed to BioMarin, on track.

View article

2018

Spinouts

UCLB spinouts raise a total of $460.9m in their IPOs on NASDAQ.

Spinouts

Gene Therapy

Orchard Therapeutics acquires rare disease gene therapy portfolio from GSK.

View article

Announcements

Investments

Freeline

Freeline secures over £88m

Series B funding to drive its programmes through clinical development.

View article
Orchard Therapeutics logo

Orchard Therapeutics announces $150m

Series C financing to advance gene therapy pipeline.

View article
Logo

Engitix closes £5m

Series A financing to progress liver disease and pancreatic cancer treatment.

View article
Endomag Logo

Endomag secures $10m

Series C funding to establish better breast cancer care.

View article

Awards

Endomag Logo

UCLB spinout Endomag wins two prestigious awards: The Queen's Award for Enterprise in Innovation, Institute of Physics' British Business Innovation Award.

View article
Orchard Therapeutics logo

Orchard Therapeutics win GUV Deal of the Year Award, for its oversubscribed $110m Series B funding round.

View article

2017

Biopharm advancements

Blood test tube

BioMarin provides 1.5 years of clinical data for Valoctocogene Roxaparvovec gene therapy for severe haemophilia A, developed by Prof. Amit Nathwani, UCL Cancer Institute.

View article

First patient treated in trial of a novel liver dialysis device, DIALIVE.

View article

Investments

Research

Apollo Therapeutics launches its first four drug discovery programmes in collaboration with academics at all three partner universities, spanning a variety of disease areas and drug modalities.

View article
Orchard Therapeutics logo

Orchard Therapeutics announces $110m

Series B financing to advance transformative gene therapy pipeline.

View article
Autolus

Autolus secures $80m

Series C funding to establish clinical proof of concept for three novel haematological cancer programmes.

View article

Spinouts

Puridify

UCLB spinout company Puridify acquired by GE Healthcare.

View article

Collaborations

Chirp

UCLB spinout Chirp collaborates with Hijinx to bring toys to life.

View article

2016

Launches

logo

£50m

UCL Technology Fund launched to support academics whose research has commercial potential.

View article

£40m

Apollo Therapeutics Fund launched to drive therapeutic innovation.

View article

Advancements

Biopharm advancements

BioMarin provides positive data from its Phase 1/2 clinical trial, showing that patients with haemophilia A had improved and sustained clotting function.

View article

Investments

Achilles Therapeutics logo

Achilles Therapeutics raises £13.2m

Series A funding to develop immunotherapies for cancer.

View article
Autolus

Autolus secures £40m

Series B funding to develop its proprietary pipeline of engineered T-cell products.

View article